Search / Trial NCT00000943

A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of December 08, 2024

Completed

Keywords

Lymphocytes Interleukin 2 Drug Therapy, Combination Aids Vaccines Cd4 Lymphocyte Count Cell Division Hiv Core Protein P24 Anti Hiv Agents Hiv Therapeutic Vaccine

ClinConnect Summary

Proliferative responses to HIV antigens are either absent or of small magnitude in HIV-infected patients, even in the early stages of infection when vigorous proliferative responses to recall antigens are still seen. Remune consists of an inactivated, gp120-depleted virus intended to stimulate HIV-specific immune responses. Remune has been reported to increase lymphocyte proliferative responses to HIV antigens in patients with high CD4 cell counts. Many other T-cell-dependent responses are also impaired in HIV-infected patients, such as after vaccination with hepatitis A or B vaccine. In th...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Patients may be eligible for this study if they:
  • Have completed at least 60 weeks of treatment on ACTG 328.
  • Are willing to continue on their assigned ACTG 328 treatment until after they have completed 24 weeks on this substudy.
  • Have a viral load less than or equal to 2,000 copies/ml.
  • Exclusion Criteria
  • Patients will not be eligible for this study if they:
  • Have an active opportunistic (HIV-related) infection.
  • Are pregnant or breast-feeding.
  • Have taken or are taking certain medications that are prohibited.

Trial Officials

Hernan Valdez

Study Chair

Michael Lederman

Study Chair

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Iowa City, Iowa, United States

New York, New York, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials